Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Gramicidin S + cetylpyridinium chloride** is a combination of two antimicrobial agents used primarily for topical antiseptic and oral/oropharyngeal disinfection purposes. **Gramicidin S** is a cyclic peptide antibiotic that disrupts bacterial cell membranes, exhibiting potent activity against gram-positive bacteria. **Cetylpyridinium chloride (CPC)** is a cationic quaternary ammonium compound with broad-spectrum antimicrobial activity, acting as an antiseptic by disrupting the cell membranes of bacteria, fungi, and some enveloped viruses, leading to rapid killing of gram-positive bacteria and moderate fungicidal effect[1][2][3][5]. This combination is used in mouth rinses, lozenges, and similar preparations for reducing oral and respiratory tract pathogens, plaque, gingivitis, and for prophylaxis/treatment of oropharyngeal infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gramicidin s + cetylpyridinium chloride.